

LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

1/11/08  
JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
DEBRA J. MILASINCIC, Ph.D.  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPERT  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.

LISA DIROCCO TYNER  
HATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.  
JOHN D. LANZA

\$1653  
PATENT AGENTS  
THEODORE R. WEST  
JONATHAN M. SPARKS, Ph.D.  
ANDRINA WILLIAMS ZINK

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.  
DEBORAH L. NAGLE, Ph.D.  
ANNE JACQUELINE WIZEMAN, Ph.D.  
BRIAN C. TRINQUE, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

February 3, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 09/972772  
For: *Therapeutic Agents and Methods of Use Thereof for the Modulation of Angiogenesis*  
Inventors: Olson, Gary L. *et al.*  
Filed: October 5, 2001  
Our Ref. No.: PPI-106CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB-08;
3. Copies of references cited in PTO Form SB-08 (2);
4. Copy of the International Search Report; and
5. A Return Postcard.


No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

7/3/04  
Date  
Jane E. Remillard  
Jane E. Remillard, Esq., Reg. No. 38,872

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Jane E. Remillard  
Jane E. Remillard, Esq.  
Registration No. 38,872  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Olson, Gary L. *et al.*

Serial No.: 09/972772

Filed: October 5, 2001

For: *Therapeutic Agents and Methods of Use Thereof  
for the Modulation of Angiogenesis*

Attorney Docket No.: PPI-106CP

Group Art Unit: 1653

Examiner: Russel, J.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

2/3/04

Date of Signature and of Mail Deposit

By:

  
Jane E. Remillard, Esq.  
Registration No. 38,872  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

The present application is a Continuation-in-Part Application of U.S. Serial No. 09/704251, filed November 1, 2000 (Atty. Docket No. PPI-106). The majority of the references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application and, in accordance with 37 CFR §1.98(d), copies of references A1-C1, C3, C5-C12 are not enclosed, but will be provided upon request. Reference ID Nos. C2 and C4 were cited in an International Search Report during the prosecution of PCT/US03/13623 dated November 13, 2003

02/11/2004 09:00:00 09972772


01 FC:1806 180.00 DA

which corresponds to the above referenced application. A copy of the report and two cited publications are enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP




Jane E. Remillard, Esq.  
Registration No. 38,872  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: 2/3/04

GAD/JER/MCL/JMS/alf  
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO <b>PPI-106CP</b>	SERIAL NO. <b>09/972772</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT <b>Olson, Gary L. et al.</b>	
				FILING DATE <b>October 5, 2001</b>	GROUP <b>1653</b>



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,135,919	8/92	Folkman <i>et al.</i>	514	56	
	A2	5,180,738	1/93	Kishimoto <i>et al.</i>	514	475	
	A3	5,290,807	3/94	Folkman <i>et al.</i>	514	475	
	A4	5,648,382	7/97	Billington <i>et al.</i>	514	475	
	A5	5,698,586	12/97	Kishimoto <i>et al.</i>	514	475	
	A6	5,767,293	6/98	Oku <i>et al.</i>	549	332	
	A7	5,789,405	8/98	Oku <i>et al.</i>	514	227.8	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A8	WO 9959986	11/99	PCT				
	A9	WO 9961432	12/99	PCT				
	A10	WO 0069472	11/00	PCT				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	A11	Denmeade SR, <i>et al.</i> "Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen." <i>Cancer Res.</i> 1998 Jun 15;58(12):2537-40
	A12	Griffith EC, <i>et al.</i> "Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2." <i>Proc Natl Acad Sci U S A.</i> 1998 Dec 22;95(26):15183-8
	A13	Griffith EC, <i>et al.</i> "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin". <i>Chem Biol.</i> 1997 Jun;4(6):461-71
	A14	Han CK, <i>et al.</i> "Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2." <i>Bioorg Med Chem Lett.</i> 2000 Jan 3;10(1):39-43
	A15	Landquist, JK "Some Degradation Products of Fumagillin" <i>J. Chem. Soc.</i> 1956: 4237-4245
	A16	Tarbell <i>et al.</i> "The structure of fumagillin" <i>Am. Chem. Soc.</i> 1960 Feb 20; 82:1005-1007
Examiner		Date Considered
EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

Date Considered

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV. 7/90 <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>		ATTY DOCKET NO. <b>PPI-106CP</b>	SERIAL NO. <b>09/972772</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Olson, Gary L. et al.</b>	
		FILING DATE <b>October 5, 2001</b>	GROUP <b>1653</b>



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C1	4,703,107	10/87	Monsigny <i>et al.</i>	530	330	
	C2	5,180,735	01/93	Kishimoto <i>et al.</i>	514	443	
	C3	6,017,954	01/00	Folkman <i>et al.</i>	514	475	
	C4	2002/0193298 A1	12/02	Olson <i>et al.</i>	514	12	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	C5	EP 0 354 767 A1	02/90	EPO				
	C6	EP 0 357 061 A1	03/90	EPO				
	C7	EP 0 359 036 A1	03/90	EPO				
	C8	EP 0 387 650 A1	09/90	EPO				
	C9	EP 0 415 294 A2, A3	03/91	EPO				
	C10	WO 98/13059 A1	04/98	WO				
	C11	WO 98/56372 A1	12/98	WO				
	C12	WO 00/64486 A2, A3	11/00	WO				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

C11	De Marre, A. <i>et al.</i> "Synthesis and evaluation of macromolecular prodrugs of mitomycin C," <i>Journal of Controlled Release</i> 36(1/2):87-97 (Sep 1995).
C12	Nichifor, M. <i>et al.</i> "Chemical and enzymatic hydrolisis of dipeptide derivatives of 5-fluorouracil," <i>Journal of Controlled Release</i> 47:271-281 (1997).
Examiner	Date Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	